JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

Search

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

428.63 -1.11

Overview

Share price change

24h

Current

Min

425.19

Max

435.29

Key metrics

By Trading Economics

Income

31M

-42M

Sales

76M

213M

EPS

-1.9

Profit margin

-19.869

Employees

528

EBITDA

31M

-39M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+16.21% upside

Dividends

By Dow Jones

Next Earnings

4 lis 2025

Market Stats

By TradingEconomics

Market Cap

2.8B

9.7B

Previous open

429.74

Previous close

428.63

News Sentiment

By Acuity

36%

64%

111 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 paź 2025, 23:50 UTC

Hot Stocks

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 paź 2025, 23:25 UTC

Earnings

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 paź 2025, 23:18 UTC

Earnings

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 paź 2025, 22:20 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 paź 2025, 22:13 UTC

Earnings

Wal-Mart de Mexico Net Profit Falls in 3Q

28 paź 2025, 21:38 UTC

Earnings

Correction to Visa Sales Jump Article

28 paź 2025, 21:17 UTC

Earnings

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 paź 2025, 21:07 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- Update

28 paź 2025, 21:02 UTC

Earnings

Mondelez Tempers Outlook as Costs Rise

28 paź 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 paź 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 paź 2025, 23:02 UTC

Earnings

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 paź 2025, 23:01 UTC

Earnings

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 paź 2025, 22:46 UTC

Earnings

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 paź 2025, 22:45 UTC

Earnings

SK Hynix 3Q Net KRW12.6T >000660.SE

28 paź 2025, 22:44 UTC

Earnings

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 paź 2025, 22:43 UTC

Earnings

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 paź 2025, 22:42 UTC

Earnings

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 paź 2025, 22:40 UTC

Earnings

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 paź 2025, 22:40 UTC

Earnings

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 paź 2025, 22:20 UTC

Earnings

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 paź 2025, 22:02 UTC

Earnings

Review & Preview: Earnings Extravaganza -- Barrons.com

28 paź 2025, 21:42 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

28 paź 2025, 21:42 UTC

Market Talk
Earnings

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 paź 2025, 21:20 UTC

Earnings

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 paź 2025, 21:19 UTC

Earnings

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 paź 2025, 21:18 UTC

Earnings

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

16.21% upside

12 Months Forecast

Average 506.43 USD  16.21%

High 590 USD

Low 266 USD

Based on 16 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

14

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

111 / 373 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat